InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.40
(
0.45%
)
Bitcoin
62,256.56
(
-1.43%
)
Post# of 21373
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DayDreeming

Send PM Follow Ignore
Followers 4
Posts 687
Boards Moderated 0
Alias Born 09/27/2016

DayDreeming

Re: None

Tuesday, 09/25/2018 5:14:20 PM

Tuesday, September 25, 2018 5:14:20 PM

Post# of 21373
Dream on Redman!!!!!! Keep hanging those carrots on the stick and sooner or later your stick can't support all of them....LOL

"Although osteosarcoma will be our first target for this drug, the preclinical data show CycloSamTM may be superior to Xifigo, a radiopharmaceutical marketed by Bayer ($464 million sales 2017) for the treatment of bone metastases. Our drug could also be a better choice for bone marrow ablation," stated Michael Redman, CEO of Oncolix. "Furthermore, if we enter into this license agreement, we will have a strengthened pipeline of drug candidates."

Death smiles on us all. All a man can do is smile back.

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up